CAS: 199463-33-7; N-(4-Fluorophenyl)-4,5-Dimethyl-6-(1-Methyl-3,4-Dihydroisoquinolin-2(1H)-yl)Pyrimidin-2-Amine

该化合物是一种新型化合物,被归类为钾竞争酸阻塞器(P-CAB),主要用于治疗酸性肠胃紊乱,有选择性地抑制气态H+/K+-ATPase酶,在气态酸分泌中起着关键作用.这一机制使Revaprazan能够有效减少气态酸性,从胃肠杆菌复发病和胃溃疡等条件中缓解,该物质的特点与其传统的质子泵抑制剂相比具有高度的能量和迅速行动.Revaprazan通常通过口头管理,表现出一种有利的药效皮质特征,包括良好的生物利用率和相对较长的半衰期,这支持了一次的剂量.此外,人们注意到它对于药物相互作用的潜力较低,使它成为病人在多种药物上的适当选择.

结构式图片

上下游产品

2-Chloro-5,6-Dimethyl-4-(1-Methyl-1,2,3,4-Tetrahydroisoquinolin-2-yl)Pyrimidine 178308-12-8

合成工艺路线路线简述

    2,4-二氯-5,6-二甲基嘧啶,1-甲基-1,2,3,4-四氢异喹啉置于双(三甲基硅烷基)氨基钾,三乙胺体系中,用 四氢呋喃,N,N-二甲基甲酰胺 用作溶剂,化学反应 16.0H,反应生成盐酸瑞伐拉赞
    参考文献:具有抗癌活性的n-杂芳基胺的合成:N-杂芳基烷基醚与胺的亲核胺化作用.
    标题:具有抗癌活性的n-杂芳基胺的合成:N-杂芳基烷基醚与胺的亲核胺化作用.
    摘要:描述了n-杂芳基烷基醚与各种胺的温和胺化方案.通过使用简单易用的碱基作为启动子通过c-o键裂解来实现这种转化,从而提供了一种新的胺化策略来使用多种抗癌活性化合物.出色的官能团兼容性,可扩展性,广泛的底物范围以及多种药物的容易衍生化,突出了这项工作.
    Doi:10.1021/acs.Orglett.9B01711

    海关参考信息

    专利信息


    专利号:US-2008280855-A1
    优先权日:2005-06-22
    标 题 :Process For the Production of Intermediates For the Preparation of Tricyclic Benzimidazoles
    发明人:CHIESA MARIA VITTORIA; PALMER ANDREAS; BUHR WILM; ZIMMERMANN PETER JAN; BREHM CHRISTOF; SIMON WOLFGANG-ALEXANDER; POSTIUS STEFAN; KROMER WOLFGANG; ZANOTTI-GEROSA ANTONIO
    权利人:NYCOMED GMBH
    摘要:The invention relates to a process for the synthesis of compounds of the formula 1-a and compounds of the formula 1-b. n n n n n n n n n n The compounds of the formula 1-a and the compounds of the formula 1-b, in which the substituents R1, R2, R3, and Ar have the meanings indicated in the description, are valuable intermediates for the preparation of pharmaceutically active compounds.

    专利号:WO-02088088-A9
    优先权日:2001-04-27
    标题 :Process for preparing 1-methyl-1,2,3,4-tetrahydroisoquinoline or a salt thereof
    发明人:BREEN GARY FRANCIS; FORTH MICHAEL ANTHONY; POPKIN MATTHEW EDWARD
    权利人:SB PHARMCO INC; BREEN GARY FRANCIS; FORTH MICHAEL ANTHONY; POPKIN MATTHEW EDWARD
    摘要:The invention provides a process for preparing 1-methyl-1,2,3,4-tetrahydroisoquinoline of formula (A), or a salt thereof, the process comprising: (i) reacting N-(2-chloroethyl)-α-methylbenzylamine of formula (B), or a salt thereof, with a Lewis acid such as AlCl3, and (ii) causing or allowing cyclisation to 1-methyl-1,2,3,4-tetrahydroisoquinoline. The invention also provides a process for preparing 1-methyl-1,2,3,4-tetrahydroisoquinoline of formula (A), or a salt thereof, the process comprising: (i) reacting a N-(2-haloethyl)-α-methylbenzylamine, or a salt thereof, with a Lewis acid and (ii) causing or allowing cyclisation to 1-methyl-1,2,3,4-tetrahydroisoquinoline at a temperature of ≤130°C. The use of N-(2-chloroethyl)-α-methylbenzylamine and/or lower cyclisation temperatures decreases the amount of certain impurities formed in the reaction. In other aspects of the invention, the 1-methyl-1,2,3,4-tetrahydroisoquinoline can be used in the synthesis of 5,6-dimethyl-2-(4-fluorophenylamino)-4-(1-methyl-1,2,3,4-tetrahydroisoquinolin-2-yl)pyrimidine (SB 641257, YH1885), a pharmaceutically active reversible proton pump inhibitor.

    专利号:CN-114616340-A
    优先权日:2019-07-09
    标题 :Process for the synthesis of anticoagulant polysaccharides

    专利号:CN-118978468-A
    优先权日:2024-07-31
    标 题 :Synthesis method of voronoi fumarate intermediate

    专利号:CN-119798142-A
    优先权日:2025-01-15
    标 题 :Asymmetric catalytic synthesis method of chiral 3-aminopiperidine and derivative thereof
    重庆康乐制药有限公司
    ⚠️ 未注册 · 未认证企业
    ⚠️ 该商家尚未完成注册及企业认证,请用户仔细辨别,谨慎交易。
    数据来源于公开网络搜索,平台未作核实,请自行辨别。
    🏢敬请 企业认领
    🏬开设公司展台
    📢获取免费会员权益
    🎖️点亮专属注册企业标签
    📇展现公司完整信息 样本查看立即注册认领 →
    网址: http://www.cqkl.com.cn
    企业联系电话:023-68980207👤
    📞重庆康乐制药有限公司 ⚠️参考联系方式
    联系人:李伟
    电话:023-68980207


    邮箱:cqkl@cqkl.com.cn
    通信地址: 重庆(长寿)化工园区,化中大道4号
    邮编: 400061
    🆔 联系时候可告知是从"百琢研"平台获取的信息.
    ⚠️ 声明: 该企业未认证、未认领,请自行辨别信息的真实性和可靠性。咨询或交易时请注意风险评估与信息核实,百琢研不参与任何交易。企业认领注册入口→

    地址:重庆(长寿)化工园区,化中大道4号
    ⚠️ 未注册 · 未认证企业
    注册入口 备注: 📌 数据来源说明:本展台内容基于各搜索引擎等公开数据整理,仅作展示用途。请用户自行辨别
    ✉️ 若企业需抹除展台内容或有异议, 请通过页面底部联系方式告知我们,我们会尽快处理。
    第 1 / 1 页
    现货

    供应商参考报价(招募中)

    品牌试剂参考报价(招募中)

    📌 第三方产品分析报告

    ✅ COA系统入驻 | 共享模式

    主要参考文献


    1: Kim JH, Kim EH, Ock C, Hong H, Kim YJ, Kwon KA, Park DK, Hahm KB. Mitigating endoplasmic reticulum stress with revaprazan ameliorates stress-related mucosal disease. J Gastroenterol Hepatol. 2012 Jan;27(1):120-9. doi: 10.1111/j.1440-1746.2011.06838.x. doi: 10.5009/gnl14135.
    3: Choi HY, Noh YH, Jin SJ, Kim YH, Kim MJ, Sung H, Jang SB, Lee SJ, Bae KS, Lim HS. Bioavailability and tolerability of combination treatment with revaprazan 200 mg + itopride 150 mg: a randomized crossover study in healthy male Korean volunteers. Clin Ther. 2012 Sep;34(9):1999-2010. doi: 10.1016/j.clinthera.2012.07.004. Epub 2012 Aug 1. Korean. doi: 10.3164/jcbn.11-94. Epub 2012 Jul 20.
    7: Park SY. [Effect of acid pump antagonist (Revaprazan, Revanex(R)) on the result of 13C urea breath test in the patients with Helicobacter pylori associated peptic ulcer disease]. Korean J Gastroenterol. 2011 Jan;57(1):1-2. Korean. doi: 10.1016/j.ijpharm.2011.01.059. Epub 2011 Feb 2. doi: 10.1159/000339882. Epub 2012 Aug 14.

    合成参考文献


    摘要:S92 | FLUOROPHARMA | List of ~340 ATC classified fluoro-pharmaceuticals | DOI:10.5281/zenodo.5979646
    📝 需求与反馈
    尽可能描述清楚需求与问题信息
    ×

    通知